Acceptance of sbp-101 abstract for poster presentation at american association for cancer research (aacr)

Minneapolis, march 01, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for sbp-101, a proprietary polyamine analogue, has been accepted for poster presentation at the american association for cancer research (aacr), which will be held april 14-19, 2023. the work reflects the company's on-going collaboration with johns hopkins university school of medicine.
PBLA Ratings Summary
PBLA Quant Ranking